Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.

Upadhyay, Vivek A; Brunner, Andrew M; Fathi, Amir T

Upadhyay, Vivek A; Brunner, Andrew M; Fathi, Amir T.

Afiliação

Upadhyay VA; Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Brunner AM; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, United States.
Fathi AT; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, United States. Electronic address: atfathi@partners.org.

Pharmacol Ther ; 177: 123-128, 2017 Sep.

Article em En | MEDLINE | ID: mdl-28315358

Assuntos

Isocitrato Desidrogenase/antagonistas & inibidores; Leucemia Mieloide Aguda/tratamento farmacológico; Animais; Humanos; Isocitrato Desidrogenase/genética; Isocitrato Desidrogenase/metabolismo; Leucemia Mieloide Aguda/genética; Mutação; Prognóstico

Palavras-chave

Acute myeloid leukemia; IDH; Isocitrate dehydrogenase

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Isocitrato Desidrogenase Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google